European Companies Search Engine
EU funding (€13.6M): EARLY DYNAMIC SCREENING FOR COLORECTAL CANCER VIA NOVEL PROTEIN BIOMARKERS REFLECTING BIOLOGICAL INITIATION MECHANISMS Hor1 Jan 2023 EU Research and Innovation programme "Horizon"
Overview
Text
EARLY DYNAMIC SCREENING FOR COLORECTAL CANCER VIA NOVEL PROTEIN BIOMARKERS REFLECTING BIOLOGICAL INITIATION MECHANISMS
DIOPTRA aims to introduce a front-line screening tool that will consider risk factors and protein biomarkers for pinpointing individuals at a high risk for colorectal cancer (CRC) incidence. Tissue & blood samples will be examined towards a discriminative set of prognostic proteins that are detectable via standard bloodwork and can indicate a need for further evaluation (i.e. colonoscopy). Other data (e.g. medical, behavioural) will also be considered as potential risk factors. Artificial intelligence (AI) will be leveraged for assessing prognostic power, while personalised behavioural change will be promoted based on modifiable risk factors. Given the low citizen participation on CRC screening across EU, DIOPTRA seeks to broaden the evaluated population, boosting participation rates and bypassing age screening thresholds. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening’.
Funded Companies:
Source: https://cordis.europa.eu/project/id/101096649
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Cambridge Medical Academy Ltd., Cambridge.
The visualizations for "Cambridge Medical Academy Ltd. - EU funding (€13.6M): EARLY DYNAMIC SCREENING FOR COLORECTAL CANCER VIA NOVEL PROTEIN BIOMARKERS REFLECTING BIOLOGICAL INITIATION MECHANISMS"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
